Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma
Open Access
- 17 March 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (3) , e0120181
Abstract
Approximately 50% of patients with uveal melanoma (UM) will develop metastatic disease, usually involving the liver. The outcome of metastatic UM (mUM) is generally poor and no standard therapy has been established. Additionally, clinicians lack a validated prognostic tool to evaluate these patients. The aim of this work was to develop a reliable prognostic nomogram for clinicians. Two cohorts of mUM patients, from Veneto Oncology Institute (IOV) (N=152) and Mayo Clinic (MC) (N=102), were analyzed to develop and externally validate, a prognostic nomogram. The median survival of mUM was 17.2 months in the IOV cohort and 19.7 in the MC cohort. Percentage of liver involvement (HR 1.6), elevated levels of serum LDH (HR 1.6), and a WHO performance status=1 (HR 1.5) or 2–3 (HR 4.6) were associated with worse prognosis. Longer disease-free interval from diagnosis of UM to that of mUM conferred a survival advantage (HR 0.9). The nomogram had a concordance probability of 0.75 (SE .006) in the development dataset (IOV), and 0.80 (SE .009) in the external validation (MC). Nomogram predictions were well calibrated. The nomogram, which includes percentage of liver involvement, LDH levels, WHO performance status and disease free-interval accurately predicts the prognosis of mUM and could be useful for decision-making and risk stratification for clinical trials.Keywords
This publication has 45 references indexed in Scilit:
- Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanomaHuman Pathology, 2013
- Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanomaAnnals of Oncology, 2013
- The potential role of sunitinib targeting melanomasExpert Opinion on Investigational Drugs, 2013
- Genomic Profile of 320 Uveal Melanoma Cases: Chromosome 8p-Loss and Metastatic OutcomeInvestigative Ophthalmology & Visual Science, 2013
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialThe Lancet Oncology, 2012
- Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in EuropeEuropean Journal of Cancer, 2012
- Ocular melanomaCurrent Opinion in Oncology, 2012
- Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up studyBritish Journal of Cancer, 2012
- Therapeutic Options in Metastatic Uveal Melanoma2011
- Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal OriginClinical Cancer Research, 2011